Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the vaccine delivery technologies market
- Related reports
- Upcoming related reports
ANTIGEN TYPES FOR HUMAN VACCINES
- Historic overview of antigen development for vaccines
- Live-attenuated pathogens
- Inactivated/killed pathogens
- Protein-based subunit or toxoid vaccines
- Polysaccharide subunit vaccines
- DNA/RNA vaccines
RATIONALE FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY SYSTEMS
- Novel delivery vehicles could improve the efficacy of subunit vaccines
- Improved antigen stability is a key need, particularly for mucosal
administration routes
- Delivery vehicles with additional adjuvant qualities could enable the
development of vaccines against challenging indications
CHALLENGES FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY VEHICLES
- Cost containment could become a key hurdle for novel vaccine delivery
vehicles
- More research is needed to understand the molecular mechanisms of antigen
delivery
- The conservative attitude of regulators towards novel adjuvants and
delivery vehicles is a key challenge
- Various new technologies are in development as antigen delivery vehicles
BACTERIAL/VIRAL VECTORS
- Summary
- General considerations
- Bacterial/viral vector vaccines in development
- Acambis/Sanofi Pasteur - ChimeriVax technology
- Crucell - Advax technology
- Bavarian Nordic - MVA-BN
- Datamonitor assessment
LIPOSOMES
- Summary
- General considerations
- Liposomal vaccines in development
- Merck Serono - Stimuvax/L-BLP25
- NasVax - VaxiSome technology
- Datamonitor assessment
VIROSOMES
- Summary
- General considerations
- Marketed and pipeline virosomal vaccines
- Crucell - Immunopotentiating reconstituted influenza virosome (IRIV)
technology
- Pevion Biotech - PeviPro and PeviTer virosome technologies
- Datamonitor assessment
VIRUS-LIKE PARTICLES
- Summary
- General considerations
- Marketed and pipeline VLP vaccines
- Cytos Biotechnology - Immunodrug platform
- Novavax - baculovirus-based VLPs
- Others
- Datamonitor assessment
ISCOM/ISCOMATRIX
- Summary
- General considerations
- ISCOM/ISCOMATRIX-based vaccines in development
- CSL and licensees - ISCOMATRIX
- Datamonitor assessment
MICROPARTICLES/NANOPARTICLES
- Summary
- General considerations
- Micro-/nanoparticle technologies in development for vaccines
- PLGA - poly(-lactide co-glycolide)
- Chitosan
- Datamonitor assessment
BIBLIOGRAPHY
APPENDIX
- Contributing experts
- Academic key opinion leaders
- Industry key opinion leaders
- Conferences
- Report methodology
TABLES
- Table: Key marketed live-attenuated vaccines, 7MM, May 2009
- Table: Summary of key antigen delivery technologies in development
- Table: Viral and bacterial vector-based vaccines for prophylactic vaccine
applications, May 2009
- Table: Viral and bacterial vector-based vaccines for therapeutic vaccine
applications, May 2009
- Table: SWOT analysis: bacterial/viral vector based vaccine delivery
- Table: Key pipeline liposomal vaccines
- Table: SWOT analysis - liposome-based vaccine delivery
- Table: Key marketed and pipeline virosomal vaccines
- Table: SWOT analysis - virosome-based vaccine delivery
- Table: Key marketed and pipeline virus-like particle (VLP)-based vaccines
- Table: SWOT analysis - virus-like particle (VLP)-based vaccine delivery
- Table: Key pipeline vaccines based on ISCOMATRIX
- Table: SWOT analysis - ISCOM/ISCOMATRIX-based vaccine delivery
- Table: Key micro- and nanoparticle technologies in development
- Table: SWOT analysis - microparticle-/nanoparticle-based vaccine delivery
FIGURES
- Figure: History of vaccine antigen design and delivery
- Figure: Unmet needs in antigen delivery
- Figure: Drivers and resistors for the development of antigen delivery
vehicles
- Figure: Public sector immunization cost per child in the US ($), 1975 -
2008
- Figure: Vector vaccines
- Figure: Liposomal vaccine delivery
- Figure: Virosome structure
- Figure: Production of virus-like particles (VLPs)
|
Related Report
|
View Cart
